Lantern Pharma

LTRN

Market cap $42.2M

DALLAS--(BUSINESS WIRE)--LP-184 Clinical Insights, KOL Webinar & Future Plans.

Palantir Technologies (NASDAQ: PLTR) has grown into a dominant force in AI-driven data analytics, securing lucrative government contracts and expanding its mission-critical intelligence business.

Lantern Pharma Inc. ( LTRN ) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors November 20, 2025 4:30 PM EST Company Participants Panna Sharma - President, CEO & Director Kishor Bhatia - Chief Scientific Officer & Scientific Consultant Reggie Ewesuedo Conference Call Participants Igor Astsaturov Presentation Panna Sharma President, CEO & Director Okay. Thank you, everyone, for joining us today for our LP-184 clinical trial results webinar.

Lantern Pharma Inc. ( LTRN ) Q3 2025 Earnings Call November 13, 2025 9:00 AM EST Company Participants Panna Sharma - President, CEO & Director David Margrave - CFO & Secretary Presentation Operator Good morning, and welcome to our third quarter 2025 earnings call. As a reminder, this call is being recorded [Operator Instructions].

DALLAS--(BUSINESS WIRE)--Q3 Press Release - BTM.

DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET.

DALLAS--(BUSINESS WIRE)--Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT.

DALLAS--(BUSINESS WIRE)--LP-284 at 25th LL&M Congress & CMR.

DALLAS--(BUSINESS WIRE)--Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025.

DALLAS--(BUSINESS WIRE)--Clinical Trial Results, LP-184.